Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia

British Journal of Haematology

Volumn 143, Issue 4, 2008, Pages 541-547

  Brethon, Benoit ^a   Yakouben, Karima ^b   Oudot, Caroline ^c   Boutard, Patrick ^d   Bruno, Bénédicte ^e   Jérome, Cécile ^f   Nelken, Brigitte ^e   De Lumley, Lionel ^c   Bertrand, Yves ^g   Dalle, Jean Hugues ^b   Chevret, Sylvie ^a   Leblanc, Thierry ^a   Baruchel, André ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Institut de Cancerologie de la Loire   (France)

^g HÔPITAL DEBROUSSE   (France)

Author keywords

Acute myeloid leukaemia; Anti CD33; Children; Gemtuzumab ozogamicin; Mylotarg

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASPERGILLOSIS; BLOOD TOXICITY; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINEMIA; MALE; MONOTHERAPY; MYCOSIS; PARANASAL SINUS DISEASE; PRIORITY JOURNAL; SEPTICEMIA; SINUSOIDAL OBSTRUCTIVE SYNDROME; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

EID: 54849432031     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07370.x     Document Type: Article

References (35)

1. Arceci, R.J., Sande, J., Lange, B., Shannon, K., Franklin, J., Hutchinson, R., Vik, T.A., Flowers, D., Aplenc, R., Berger, M.S., Sherman, M.L., Smith, F.O., Bernstein, I. Sievers, E.L. (2005) Safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) in pediatric patients with advanced CD33-positive acute myeloid leukemia. Blood, 106, 1183 1188.
2. Becton, D., Dahl, G.V., Ravindranath, Y., Chang, N.M., Behm, F.G., Raimondi, S.C., Head, D.R., Stine, K.C., Lacayo, N.J., Sikic, B.I., Arceci, R.J. Weinstein, H. (2006) Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood, 107, 1315 1324.
3. Brethon, B., Auvrignon, A., Galambrun, C., Yakouben, K., Leblanc, T., Bertrand, Y., Leverger, G. Baruchel, A. (2006a) Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia. BMC Cancer, 6, 172.
4. Brethon, B., Auvrignon, A., Cayuela, J.M., Lapillonne, H., Leverger, G. Baruchel, A. (2006b) Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine. Haematologica, 91, 419 421.
5. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research, 7, 1490 1496.
6. Burnett, A.K., Kell, W.J., Goldstone, A.H., Milligan, D., Hunter, A., Prentice, A.G., Russell, N.H., Gibson, B., Wheatley, K. Hills, R.K. (2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood (ASH annual meeting abstracts), 108, abstract 13.
7. Cohen, A.D., Luger, S.M., Sickles, C., Mangan, P.A., Porter, D.L., Schuster, S.J., Tsai, D.E., Nasta, S., Gewirtz, A.M. Stadtmauer, E.A. (2002) Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplantation, 30, 23 28.
8. Creutzig, U., Harbott, J., Sperling, C., Ritter, J., Zimmermann, M., Loffler, H., Riehm, H., Schellong, G. Ludwig, W.D. (1995) Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood, 86, 3097 3108.
9. Creutzig, U., Ritter, J., Zimmermann, M., Reinhardt, D., Hermann, J., Berthold, F., Henze, G., Jurgens, H., Kabisch, H., Havers, W., Reiter, A., Kluba, U., Niggli, F. Gadner, H. (2001) Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin- Frankfurt-Munster 93. Journal of Clinical Oncology, 19, 2705 2713.
10. Entz-Werle, N., Suciu, S., van der Werff ten Bosch, J., Vilmer, E., Bertrand, Y., Benoit, Y., Margueritte, G., Plouvier, E., Boutard, P., Vandecruys, E., Ferster, A., Lutz, P., Uyttebroeck, A., Thyss, A., Rialland, X., Norton, L., Pages, M.-P., Philippe, N., Otten, J. Behar, C., on behalf of EORTC Children Leukemia Group. (2005) Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia, 19, 2072 2081.
11. Fleischhack, G., Hasan, C., Graf, N., Mann, G. Bode, U. (1998) IDA-FLAG (idarubicine, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. British Journal of Haematology, 102, 647 655.
12. Gibson, B.E.S., Wheatley, K., Hann, I.M., Stevens, R.F., Webb, D., Hills, R.K., De Graaf, S.S.N. Harrison, C.J., for the United Kingdom Childhood Leukaemia Working Party, and the Dutch Childhood Oncology Group. (2005) Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia, 19, 2130 2138.
13. Giles, F.J., Kantarjian, H.M., Kornblau, S.M., Thomas, D.A., Garcia-Manero, G., Waddelow, T.A., David, C.L., Phan, A.T., Colburn, D.E., Rashid, A. Estey, E.H. (2001) Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92, 406 413.
14. Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D.A. Bernstein, I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chemistry, 13, 47 58.
15. Hinman, L.M., Hamann, P.R., Wallace, R., Menendez, A.T., Durr, F.E. Upeslacis, J. (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Research, 53, 3336 3342.
16. Kell, W.J., Burnett, A.K., Chopra, R., Yin, J.A., Clark, R.E., Rohatiner, A., Culligan, D., Hunter, A., Prentice, A.G. Milligan, D.W. (2003) A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood, 102, 4277 4283.
17. Lange, B.J., Smith, F.O., Feusner, J., Barnard, D.R., Dinndorf, P., Feig, S., Heerema, N.A., Arndt, C., Arceci, R.J., Seibel, N., Weiman, M., Dusenbery, K., Shannon, K., Luna-Fineman, S., Gerbing, R.B. Alonzo, T.A. (2008) Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood, 111, 1044 1053.
18. Leopold, L.H., Berger, M.S. Feingold, J. (2002) Acute and long-term toxicities associated with gemtuzumab ozogamicin (mylotarg®) therapy of acute myeloid leukemia. Clinical Lymphoma, 2 (Suppl. S29 S34.
19. Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L., Siimes, M.A., Yssing, M., Zeller, B. Gustafsson, G., on behalf of the Nordic Society of Pediatric Hematology and Oncology. (2005) Long-term results in children with AML: NOPHO-AML Study Group - report of three consecutive trials. Leukemia, 19, 2090 2100.
20. Linenberger, M.L. (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanism. Leukemia, 19, 176 182.
21. McCarthy, A.J., Pitcher, L.A., Hann, I.M. Oakhill, A. (1999) FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Medical and Pediatric Oncology, 32, 411 415.
22. McKoy, J.M., Angelotta, C., Bennett, C.L., Tallman, M.S., Wadleigh, M., Evens, A.M., Kuzel, T.M., Trifilio, S.M., Raisch, D.W., Kell, J., Deangelo, D.J. Giles, F.J. (2007) Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leukemia Research, 31, 599 604.
23. Morris, K.L., Adams, J.A. Liu, J.A. (2006) Effects of gemtuzumab ozogamicin on acute myeloid leukaemia blast cells in vitro, as a single agent and combined with other cytotoxic agents. British Journal of Haematology, 135, 509 512.
24. Perel, Y., Auvrignon, A., Leblanc, T., Vannier, J.P., Michel, G., Nelken, B., Gandemer, V., Schmitt, C., Lamagnere, J.P., de Lumley, L., Bader-Meunier, B., Couillaud, G., Schaison, G., Landman-Parker, J., Thuret, I., Dalle, J.H., Baruchel, A. Leverger, G., Group LAME of the French Society of Pediatric Hematology and Immunology. (2002) Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Journal of Clinical Oncology, 20, 2774 2782.
25. Rajvanshi, P., Shulman, H.M., Sievers, E.L. McDonald, G.B. (2002) Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 99, 2310 2314.
26. Reinhardt, D., Diekamp, S., Fleischhack, G., Corbacioglu, C., Jurgens, H., Dworzak, M., Kaspers, G., Creutzig, U. Zwaan, C.M. (2004) Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie, 27, 269 272.
27. Roman, E., Cooney, E., Harrison, L., Militano, O., Wolownik, K., Hawks, R., Foley, S., Satwani, P., Unal, E., Bhatia, M., Bradley, B., Del Toro, G., George, D., Garvin, J., van de Ven, C. Cairo, M.S. (2005) Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clinical Cancer Research, 11, 7164s 7170s.
28. Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. Bernstein, I.D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, 3678 3684.
29. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. Appelbaum, F.R., Mylotarg Study Group. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244 3254.
30. Specchia, G., Pastore, D., Carluccio, P., Spinosa, G., Giannoccaro, M., Rizzi, R., Mestice, A. Liso, V. (2007) Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Annals of Hematology, 86, 425 428.
31. Taksin, A.L., Legrand, O., Raffoux, E., de Revel, T., Thomas, X., Contentin, N., Bouabdallah, R., Pautas, C., Turlure, P., Reman, O., Gardin, C., Varet, B., de Botton, S., Pousset, F., Farhat, H., Chevret, S., Dombret, H. Castaigne, S. (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia, 21, 66 71.
32. Taussing, D.C., Pearce, D.J., Simpson, C., Rohatiner, A.Z., Lister, T.A., Kelly, G., Luongo, J.L., Danet-Desnoyre, G.H. Bonnet, D. (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood, 106, 4086 4092.
33. van der Velden, V.H., te Marvelde, J.G., Hoogeveen, P.G., Bernstein, I.D., Houtsmuller, A.B., Berger, M.S. van Dongen, J.J. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 97, 3197 3204.
34. Wadleigh, M., Richardson, P.G., Zahrieh, D., Lee, S.J., Cutler, C., Ho, V., Antin, E.P., Antin, J.H., Stone, R.M., Soiffer, R.J. DeAngelo, D.J. (2003) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102, 1578 1582.
35. Zwaan, C.M., Reinhardt, D., Corbacioglu, S., van Wering, E.R., Bokkerink, J.P., Tissing, W.J., Samuelsson, U., Feingold, J., Creutzig, U. Kaspers, G.J. (2003) Gemtuzumab ozogamicin: first clinical experience in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood, 101, 3868 3871.